XML 27 R8.htm IDEA: XBRL DOCUMENT v3.6.0.2
Net Product Sales
 12 Months Ended
Dec. 31, 2016
Revenues [Abstract]  
Net Product Sales
Product Sales
Net product sales consist of U.S. sales of EYLEA and ARCALYST. The Company received marketing approval from the FDA for EYLEA for the treatment of wet AMD in 2011, macular edema following CRVO in 2012, DME and macular edema following BRVO in 2014, and diabetic retinopathy in patients with DME in 2015. EYLEA net product sales in the United States totaled $3,323.1 million, $2,676.0 million, and $1,736.4 million for the years ended December 31, 2016, 2015, and 2014, respectively. ARCALYST net product sales totaled $15.3 million, $13.5 million, and $14.4 million for the years ended December 31, 2016, 2015, and 2014, respectively.
The Company's product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the years ended December 31, 2016, 2015, and 2014. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
 
Year Ended December 31,
 
2016
 
2015
 
2014
Besse Medical, a subsidiary of AmerisourceBergen Corporation
55
%
 
67
%
 
73
%
McKesson Corporation
28
%
 
26
%
 
20
%
Curascript SD Specialty Distribution, a subsidiary of Express Scripts
16
%
 
**

 
**

** For the periods ending December 31, 2015 and 2014, sales to Curascript SD Specialty Distribution represented less than 10% of total gross product revenue.
Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks, distribution-related fees, and other sales-related deductions. The following table summarizes the provisions, and credits/payments, for these sales-related deductions for the years ended December 31, 2016, 2015, and 2014.
 
Rebates &
Chargebacks
 
Distribution-
Related
Fees
 
Other Sales-
Related
Deductions
 
Total
Balance as of December 31, 2013
$
4,400

 
$
19,663

 
$
538

 
$
24,601

Provision related to current period sales
33,117

 
77,160

 
1,578

 
111,855

Credits/payments
(34,434
)
 
(75,657
)
 
(1,584
)
 
(111,675
)
Balance as of December 31, 2014
3,083

 
21,166

 
532

 
24,781

Provision related to current period sales
61,124

 
122,466

 
9,600

 
193,190

Credits/payments
(57,788
)
 
(95,319
)
 
(9,615
)
 
(162,722
)
Balance as of December 31, 2015
6,419

 
48,313

 
517

 
55,249

Provision related to current period sales
93,385

 
154,477

 
30,442

 
278,304

Credits/payments
(87,092
)
 
(173,325
)
 
(27,285
)
 
(287,702
)
Balance as of December 31, 2016
$
12,712

 
$
29,465

 
$
3,674

 
$
45,851